'Deeply difficult': Doug Ingram to exit Sarepta CEO

After seeing Sarepta Therapeutics through a controversial battle with the U.S. Food and Drug Administration over its gene therapy, Doug Ingram plans to retire as CEO by the end of 2026.

Kirkwood residents sue to block demolition of 1858 home as permit deadline looms

Choose St. Louis Business Journal as a preferred news source to see more of our reporting on Google. Residents argue the city ...
STAT

Trump administration officials blocked FDA effort to fast-track review of psychedelic treatment

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. Damian Garde is a reporter at ...
WSPA

Scam call blocking: Free tools that really cut down on unwanted calls

(WSPA) – 7NEWS has heard from a lot of viewers wondering how to stop harassing telemarketers and scam calls claiming to be with places like Medicare. So Here to Help looked into which spam-blocking ...